Characterization and cholesterol management in patients with cardiovascular events and/or type 2 diabetes in the Netherlands

References

• The top 10 causes of death. WHO, 2014. Available at: http://www.who.int/mediacentre/factsheets/fs310/en/[Last accessed 5 July 2016]
   Google Scholar
• Buja A, Boemo DG, Furlan P, et al. Tackling inequalities: are secondary prevention therapies for reducing post-infarction mortality used without disparities? Eur J Prev Cardiol 2014;21:222-30
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81
   PubMed Web of Science ®Google Scholar
• Kwaliteitsinstituut voor de Gezondheidszorg CBO. Multidisciplinaire richtlijn cardiovasculair risicomanagement 2006. Centraal Begeleidings Orgaan, 2006
   Google Scholar
• Rutten GEHM, De Grauw WJC, Nijpels G, et al. NHG-Standaard Diabetes mellitus type 2 (Tweede herziening). Huisarts Wet 2006;49:137-52
   Google Scholar
• Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2007;28:2375-414
   PubMed Web of Science ®Google Scholar
• Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701
   PubMed Web of Science ®Google Scholar
• Kwaliteitsinstituut voor de Gezondheidszorg CBO. Multidisciplinaire richtlijn cardiovasculair risicomanagement 2011. Centraal Begeleidings Orgaan, 2011
   Google Scholar
• NHG-Standaard Cardiovasculair risicomanagement (eerste herziening) [NHG guideline cardiovascular risk management (1st revision)]. Huisarts Wet 2012;55:14-28
   Google Scholar
• Boomsma LJ, van de Vijver PP, Lanphen JMG, et al. Landelijke Transmurale Afspraak Cardiovasculair Risicomanagement [National Multidisciplinary Agreement Cardiovascular Risk Management]. Nederlands Huisarts Genootschap, 2016
   Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315-81 published online, doi: 10.1093/eurheartj/ehw106
   PubMed Web of Science ®Google Scholar
• Hero C, Svensson AM, Gidlund P, et al. LDL cholesterol is not a good marker of cardiovascular risk in type 1 diabetes. Diabet Med 2016;33:316-23
   PubMed Web of Science ®Google Scholar
• Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther 2005;19(6):403-14
   PubMed Web of Science ®Google Scholar
• Mauskop A, Borden WB. Predictors of statin adherence. Curr Cardiol Rep 2011;13(6):553-8
   PubMedGoogle Scholar
• Jackevicius CA, Mamdani M, Tu JV, et al. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. Jama 2002;288(4):462-7
   PubMed Web of Science ®Google Scholar
• Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med 2007;167(8):847-52
   PubMedGoogle Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015;36:1012-22
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Karagiannis A. Exploring the management of statin intolerant patients: 2016 and beyond. Curr Vasc Pharmacol 2016; published online 26 February 2016, doi: 10.2174/15701611146660226150028
   Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015;11:1-23
   PubMed Web of Science ®Google Scholar
• Foody JM, Toth PP, Tomassini JE, et al. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Vasc Health Risk Manag 2013;9:719-27
   PubMedGoogle Scholar
• Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14
   PubMed Web of Science ®Google Scholar
• Stock J. Statin-associated muscle symptoms EAS Consensus Panel paper focuses on this neglected patient group. Atherosclerosis 2015;242:346-50
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016;23:636-48
   PubMed Web of Science ®Google Scholar
• Law M. Plant sterol and stanol margarines and health. BMJ (Clinical research ed) 2000;320(7238):861-4
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28:2375-414
   PubMed Web of Science ®Google Scholar
• Rutten GEHMDGW, Nijpels G, Houweling ST, et al. NHG-Standaard Diabetes mellitus type 2 (derde herziening). Huisarts Wet 2013;56:512-25
   Google Scholar
• Alnouri F, Wood D, Kotseva K, Ibrahim ME. Which statin worked best to achieve lipid level targets in a European registry? A post-hoc analysis of the EUROASPIRE III for coronary heart disease patients. J Saudi Heart Assoc 2014;26:183-91
   PubMedGoogle Scholar
• Brewer L, Mellon L, Hall P, et al. Secondary prevention after ischaemic stroke: the ASPIRE-S study. BMC Neurol 2015;15:216
   PubMed Web of Science ®Google Scholar
• Bruthans J, Mayer O Jr, De Bacquer D, et al. Educational level and risk profile and risk control in patients with coronary heart disease. Eur J Prev Cardiol 2015;23:881-90
   PubMed Web of Science ®Google Scholar
• Gyberg V, De Bacquer D, De Backer G, et al. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovasc Diabetol 2015;14:133
   PubMed Web of Science ®Google Scholar
• Heuschmann PU, Kircher J, Nowe T, et al. Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. Eur J Prev Cardiol 2015;22:1354-62
   PubMed Web of Science ®Google Scholar
• Reiner Z, De Backer G, Fras Z, et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – findings from the EUROASPIRE IV survey. Atherosclerosis 2016;246:243-50
   PubMed Web of Science ®Google Scholar
• De Backer G, Besseling J, Chapman J, et al. Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology. Atherosclerosis 2015;241:169-75
   PubMed Web of Science ®Google Scholar
• Gyberg V, Kotseva K, Dallongeville J, et al. Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study. Eur J Prev Cardiol 2015;22:753-61
   PubMed Web of Science ®Google Scholar
• van den Haak P, Heintjes E, Plat AW, et al. Determination of non-treatment with statins of high risk patients in The Netherlands. Curr Med Res Opin 2010;26:271-8
   PubMed Web of Science ®Google Scholar